Asset Details
Do you wish to reserve the book?
Synergistic apoptosis induction in myelodysplastic syndrome cells by azacitidine and PIM-2 inhibitors via nuclear factor-kappa B pathway inhibition
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Synergistic apoptosis induction in myelodysplastic syndrome cells by azacitidine and PIM-2 inhibitors via nuclear factor-kappa B pathway inhibition
Do you wish to request the book?
Synergistic apoptosis induction in myelodysplastic syndrome cells by azacitidine and PIM-2 inhibitors via nuclear factor-kappa B pathway inhibition
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Synergistic apoptosis induction in myelodysplastic syndrome cells by azacitidine and PIM-2 inhibitors via nuclear factor-kappa B pathway inhibition
2026
Overview
Background
We aimed to characterise the molecular effects of treating myelodysplastic syndrome (MDS) cells with the DNA methyltransferase inhibitor azacitidine and an PIM-2 inhibitor, focusing on their potential synergistic effects.
Methods
MDS cells were subjected to proliferation assays to assess the effects of each drug independently and in combination. The synergy of the drugs in promoting the apoptosis of MDS cells via NF-κB signalling pathway inhibition was evaluated.
Results
Our results suggested that azacitidine and the PIM-2 inhibitor have synergistic effects in inhibiting the proliferation and inducing the apoptosis of MDS cells. Furthermore, the combined application of azacitidine and PIM-2 inhibitor synergistically inhibited the NF-κB pathway, resulting in the induction of apoptosis in MDS cells.
Conclusion
Administration of a small molecule PIM-2 inhibitor in combination with the epigenetic drug azacitidine is one of the effective ways to treat MDS. Our study lays a foundation for future clinical trials in patients with MDS.
Graphical abstract
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
Subject
/ Antimetabolites, Antineoplastic - pharmacology
/ Biomedical and Life Sciences
/ Cancer
/ Cell Proliferation - drug effects
/ Drugs
/ Health Promotion and Disease Prevention
/ Humans
/ Kinases
/ Leukemia
/ Myelodysplastic Syndromes - drug therapy
/ Myelodysplastic Syndromes - metabolism
/ Myelodysplastic Syndromes - pathology
/ NF-kappa B - antagonists & inhibitors
/ Oncology
/ Protein Kinase Inhibitors - pharmacology
/ Protein Serine-Threonine Kinases
/ Proteins
/ Proto-Oncogene Proteins - antagonists & inhibitors
